Literature DB >> 34073843

Selecting and Using the Appropriate Influenza Vaccine for Each Individual.

Toshiki Sekiya1,2,3, Marumi Ohno1, Naoki Nomura1, Chimuka Handabile1, Masashi Shingai1,2, David C Jackson2,3, Lorena E Brown2,3, Hiroshi Kida1,2,4.   

Abstract

Despite seasonal influenza vaccines having been routinely used for many decades, influenza A virus continues to pose a global threat to humans, causing high morbidity and mortality each year. The effectiveness of the vaccine is largely dependent on how well matched the vaccine strains are with the circulating influenza virus strains. Furthermore, low vaccine efficacy in naïve populations such as young children, or in the elderly, who possess weakened immune systems, indicates that influenza vaccines need to be more personalized to provide broader community protection. Advances in both vaccine technologies and our understanding of influenza virus infection and immunity have led to the design of a variety of alternate vaccine strategies to extend population protection against influenza, some of which are now in use. In this review, we summarize the progress in the field of influenza vaccines, including the advantages and disadvantages of different strategies, and discuss future prospects. We also highlight some of the challenges to be faced in the ongoing effort to control influenza through vaccination.

Entities:  

Keywords:  pandemic preparedness; priming immune response; seasonal influenza vaccine; whole virus particle vaccine

Year:  2021        PMID: 34073843     DOI: 10.3390/v13060971

Source DB:  PubMed          Journal:  Viruses        ISSN: 1999-4915            Impact factor:   5.048


  99 in total

1.  Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

Authors:  Isabel Leroux-Roels; Astrid Borkowski; Thomas Vanwolleghem; Mamadou Dramé; Frédéric Clement; Eliane Hons; Jeanne-Marie Devaster; Geert Leroux-Roels
Journal:  Lancet       Date:  2007-08-18       Impact factor: 79.321

Review 2.  An inflammatory response is essential for the development of adaptive immunity-immunogenicity and immunotoxicity.

Authors:  Tetsuo Nakayama
Journal:  Vaccine       Date:  2016-10-13       Impact factor: 3.641

Review 3.  Effectiveness of 2009 pandemic influenza A(H1N1) vaccines: A systematic review and meta-analysis.

Authors:  Louise E Lansbury; Sherie Smith; Walter Beyer; Emina Karamehic; Eva Pasic-Juhas; Hana Sikira; Ana Mateus; Hitoshi Oshitani; Hongxin Zhao; Charles R Beck; Jonathan S Nguyen-Van-Tam
Journal:  Vaccine       Date:  2017-03-14       Impact factor: 3.641

4.  A non-adjuvanted whole-virus H1N1 pandemic vaccine is well tolerated and highly immunogenic in children and adolescents and induces substantial immunological memory.

Authors:  Alexandra Loew-Baselli; Borislava G Pavlova; Sandor Fritsch; Eva Maria Poellabauer; Wolfgang Draxler; Otfried Kistner; Ulrich Behre; Rudolf Angermayr; Johannes Neugebauer; Karola Kirsten; Elisabeth Förster-Waldl; Ralph Koellges; Hartmut J Ehrlich; P Noel Barrett
Journal:  Vaccine       Date:  2012-07-28       Impact factor: 3.641

Review 5.  Large animal models for vaccine development and testing.

Authors:  Volker Gerdts; Heather L Wilson; Francois Meurens; Sylvia van Drunen Littel-van den Hurk; Don Wilson; Stewart Walker; Colette Wheler; Hugh Townsend; Andrew A Potter
Journal:  ILAR J       Date:  2015

6.  Biologic and immunologic characteristics of cold-adapted influenza virus.

Authors:  H F Maassab
Journal:  J Immunol       Date:  1969-03       Impact factor: 5.422

7.  Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults.

Authors:  Christine B Turley; Richard E Rupp; Casey Johnson; David N Taylor; Julie Wolfson; Lynda Tussey; Uma Kavita; Lawrence Stanberry; Alan Shaw
Journal:  Vaccine       Date:  2011-05-30       Impact factor: 3.641

8.  Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect.

Authors:  Julie E Ledgerwood; Kathryn Zephir; Zonghui Hu; Chih-Jen Wei; Leejah Chang; Mary E Enama; Cynthia S Hendel; Sandra Sitar; Robert T Bailer; Richard A Koup; John R Mascola; Gary J Nabel; Barney S Graham
Journal:  J Infect Dis       Date:  2013-04-30       Impact factor: 5.226

9.  Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens.

Authors:  Richard D Antrobus; Lynda Coughlan; Tamara K Berthoud; Matthew D Dicks; Adrian Vs Hill; Teresa Lambe; Sarah C Gilbert
Journal:  Mol Ther       Date:  2013-12-30       Impact factor: 11.454

10.  Yearly licensing studies from 1997 to 2007 of the inactivated whole virus seasonal influenza vaccine fluval--a useful approach to pandemic vaccine development even in less well developed countries?

Authors:  Zoltan Vajo; Lajos Kosa; Istvan Szilvasy; Zsuzsanna Pauliny; Kálmán Bartha; Ildiko Visontay; Mate Jankovics; Agnes Kis; Istvan Jankovics
Journal:  Influenza Other Respir Viruses       Date:  2008-11       Impact factor: 4.380

View more
  4 in total

1.  Inactivated Whole Virus Particle Influenza Vaccine Induces Anti-Neuraminidase Antibodies That May Contribute to Cross-Protection against Heterologous Virus Infection.

Authors:  Chimuka Handabile; Toshiki Sekiya; Naoki Nomura; Marumi Ohno; Tomomi Kawakita; Masashi Shingai; Hiroshi Kida
Journal:  Vaccines (Basel)       Date:  2022-05-19

Review 2.  Recent Progress in Recombinant Influenza Vaccine Development Toward Heterosubtypic Immune Response.

Authors:  Mark B Carascal; Rance Derrick N Pavon; Windell L Rivera
Journal:  Front Immunol       Date:  2022-05-19       Impact factor: 8.786

Review 3.  Universal Flu mRNA Vaccine: Promises, Prospects, and Problems.

Authors:  Andrei A Deviatkin; Ruslan A Simonov; Kseniya A Trutneva; Anna A Maznina; Elena M Khavina; Pavel Y Volchkov
Journal:  Vaccines (Basel)       Date:  2022-04-30

4.  Special Issue-Immunity to Influenza Viruses.

Authors:  Marios Koutsakos; Sophie A Valkenburg
Journal:  Viruses       Date:  2022-02-03       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.